GGrantIndex
← Leaderboards

Rajeev Vibhakar

University Of Colorado Denver

$7,603,339
Attributed
$7,603,339
Total exposure
5
Grants
5
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $941.9K · FY200825
$1M$750K$500K$250K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$7,603,339 · 5

By mechanism

R01$6,359,138 · 3
K08$844,371 · 1
R21$399,830 · 1

Top collaborators

No co-investigators on record.

Most similar at University Of Colorado Denver

Same institution · by research overlap

Others in their field

Top investigators on “In Vivo

Research focus

In VivoTumorCellsMediatingTranslationsMedulloblastomaMalignant Neoplasm Of BrainMorbidity - Disease RateTumorigenesisChildChildhood Brain NeoplasmIn VitroChemotherapyValidationClinically RelevantPre-ClinicalSubgroupGenomicsClinical TrialsTreatment EfficacyNerve Stem CellTherapeutic TargetMolecularMouse Model

Grant awards (27)

Mechanisms of resistance to WEE1 inhibition in Myc driven medulloblastoma$383,359
R01 · FY2025 · NS · contact PI
Selective targeting of ependymoma progenitor cells via BMI1 inhibition$181,741
R21 · FY2025 · CA · contact PI
Mechanisms of resistance to WEE1 inhibition in Myc driven medulloblastoma$419,996
R01 · FY2024 · NS · contact PI
Mechanisms of resistance to WEE1 inhibition in Myc driven medulloblastoma$427,202
R01 · FY2023 · NS · contact PI
Selective targeting of ependymoma progenitor cells via BMI1 inhibition$218,089
R21 · FY2023 · CA · contact PI
Mechanisms of resistance to WEE1 inhibition in Myc driven medulloblastoma$407,702
R01 · FY2022 · NS · contact PI
Targeting Wee1 in Myc driven Medulloblasoma$255,118
R01 · FY2019 · NS · contact PI
Polo-Like Kinase 1 as a Therapeutic Target in Medulloblastoma$346,576
R01 · FY2018 · NS · contact PI
Role of EZH2 in Medulloblastoma Tumorigenesis$340,156
R01 · FY2018 · NS · contact PI
Targeting Wee1 in Myc driven Medulloblasoma$255,118
R01 · FY2018 · NS · contact PI
Polo-Like Kinase 1 as a Therapeutic Target in Medulloblastoma$346,576
R01 · FY2017 · NS · contact PI
Role of EZH2 in Medulloblastoma Tumorigenesis$340,156
R01 · FY2017 · NS · contact PI
Targeting Wee1 in Myc driven Medulloblasoma$255,118
R01 · FY2017 · NS · contact PI
Polo-Like Kinase 1 as a Therapeutic Target in Medulloblastoma$346,576
R01 · FY2016 · NS · contact PI
Role of EZH2 in Medulloblastoma Tumorigenesis$340,156
R01 · FY2016 · NS · contact PI
Targeting Wee1 in Myc driven Medulloblasoma$255,118
R01 · FY2016 · NS · contact PI
Polo-Like Kinase 1 as a Therapeutic Target in Medulloblastoma$346,576
R01 · FY2015 · NS · contact PI
Role of EZH2 in Medulloblastoma Tumorigenesis$340,156
R01 · FY2015 · NS · contact PI
Targeting Wee1 in Myc driven Medulloblasoma$254,913
R01 · FY2015 · NS · contact PI
Polo-Like Kinase 1 as a Therapeutic Target in Medulloblastoma$359,503
R01 · FY2014 · NS · contact PI
Role of EZH2 in Medulloblastoma Tumorigenesis$339,063
R01 · FY2014 · NS · contact PI
Brain Enriched MicroRNA 128a and 9/9+: Impact on medulloblastoma pathogenesis$187,380
K08 · FY2013 · NS · contact PI
Brain Enriched MicroRNA 128a and 9/9+: Impact on medulloblastoma pathogenesis$161,569
K08 · FY2012 · NS · contact PI
Brain Enriched MicroRNA 128a and 9/9+: Impact on medulloblastoma pathogenesis$163,510
K08 · FY2011 · NS · contact PI
Brain Enriched MicroRNA 128a and 9/9+: Impact on medulloblastoma pathogenesis$165,488
K08 · FY2010 · NS · contact PI
Brain Enriched MicroRNA 128a and 9/9+: Impact on medulloblastoma pathogenesis$110,819
K08 · FY2008 · NS · contact PI
Brain Enriched MicroRNA 128a and 9/9+: Impact on medulloblastoma pathogenesis$55,605
K08 · FY2008 · NS · contact PI